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Protein deﬁciency balance as a predictor of
clinical outcome in hereditary spherocytosis
Hereditary spherocytosis (HS) is the most common
non-immune hemolytic anemia aﬀecting one in
2500 individuals of northern European ancestry (1).
Mutations aﬀecting the genes SPTA1, SPTB,
ANK1, SLC4A1 and EPB42, encoding for the
erythrocyte membrane proteins spectrin a-chain,
spectrin b-chain, ankyrin, the anion exchanger 1
(band 3) and protein 4.2, respectively (2), may
underlie the disease. The mode of inheritance of HS
is often described as autosomal dominant (about
75% of HS cases), recessive or non-dominant. A
spontaneous de novo mutation is one of the
mechanisms that causes non-dominant HS (3–6).
Clinical and laboratory presentation of HS is
highly heterogeneous, ranging from an asympto-
matic condition to a severe life-threatening anemia
with transfusion dependence (7). The common
features of HS include mild anemia, jaundice and
splenomegaly. The presence of spherocytes in the
peripheral blood smear, the increase in the osmotic
fragility of red blood cells (RBC) and in reticulo-
cyte count, are the key diagnostic features of HS
(8). According to hematological and clinical pres-
entation, HS is usually classiﬁed as mild, typical or
severe (9).
The red blood cell membrane is a complex struc-
ture comprising a lipid bilayer, integral membrane
proteins and the skeleton. The vertical and hori-
zontal interactions between membrane constituents
account for the integrity, strength, and deforma-
bility of the cell. Disruption of vertical interactions
because of membrane protein deﬁciencies favor
membrane vesiculation with loss of surface area
and development of spherocytic cells. The increas-
ing rigidity of the cell membrane leads to premature
spleen sequestration and destruction of sphero-
cytes. Therefore, partial or total spleen removal
usually improves anemia in the majority of HS
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Abstract: Vertical and horizontal interactions between membrane
constituents account for integrity, strength and deformability of the
erythrocyte. Disruption of vertical interactions caused by membrane
protein deﬁciencies in hereditary spherocytosis (HS), favor membrane
vesiculation with development of spherocytic cells. Our aim was to
evaluate the hematological and clinical presentation of HS according to
the type and amount of protein deﬁciency. We studied 81 Portuguese
individuals, 71 belonging to 21 families plus 10 unrelated subjects, and
found that 51 of them were HS patients. Patients were classiﬁed as
presenting mild, typical or severe HS, according to laboratory results
and clinical follow-up. We performed screening tests and the stan-
dardized electrophoretic membrane protein analysis to identify and
quantify protein deﬁciencies. We found band 3 and ankyrin deﬁciencies
as the major causes for HS. The ratios between the value of the primary
and/or secondary protein deﬁciencies showed signiﬁcantly diﬀerent
values according to the severity of HS, and a signiﬁcant inverse corre-
lation with the severity of HS was observed. In mild HS, the ratios
between protein deﬁciencies reﬂected equivalent protein deﬁciencies,
while an unbalance was observed in typical HS, which was enhanced in
severe HS. Our data suggest that the relative quantiﬁcation of each
major membrane protein and of the ratios between the values of protein
deﬁciencies may be helpful in providing additional data about the
clinical outcome of HS.
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patients by reducing the spherocytic cell removal
(10).
Hereditary spherocytosis is not caused by a single
gene defect. The identiﬁcation of protein deﬁciency
by electrophoresis of erythrocyte membrane pro-
teins on polyacrylamide gel in the presence of
sodium dodecyl sulfate (SDS-PAGE) must be
performed prior to a DNA analysis, as the result
would indicate the gene(s) most likely aﬀected in an
individual (11). A primary protein deﬁciency may
occur isolated or it may impose deﬁciencies in one
or more proteins (secondary deﬁciencies). The
knowledge of the usual secondary protein deﬁcien-
cies associated with the primary protein deﬁciency
may be, therefore, of particular relevance. For
instance, in ankyrin deﬁciency, an associated retic-
ulocytosis masks this primary protein deﬁciency,
and only the secondary protein deﬁciency in spec-
trin and, sometimes, also in protein 4.2, reﬂect that
deﬁciency (8, 12–14).
It seems reasonable that the type and amount of
secondary protein deﬁciencies may be involved in
the hematological and clinical outcome of the
disease, as an unbalance between protein deﬁcien-
cies may account for an enhancement in membrane
destabilization.
We report a clinical, biochemical and hemato-
logical study performed in 81 Portuguese individ-
uals. Our aim was to identify and quantify the
protein deﬁciencies underlying HS, and to study the
hematological and clinical heterogeneity associated
with the protein deﬁciencies, as this could be
helpful in providing additional data about the
clinical presentation of the disease.
Materials and methods
Subjects
We studied 81 individuals from the north of
Portugal, 71 belonging to 21 families plus 10
unrelated subjects. All gave their informed consent
to participate in this study. At the beginning of this
study, some patients had already been diagnosed as
HS patients; however, the familiar studies and the
electrophoretic analysis to identify and quantify the
underlying membrane protein deﬁciency had never
been performed.
The patients were diagnosed and classiﬁed as
presenting mild, typical or severe HS, according to
hematological, biochemical (bilirubin levels) and
clinical follow-up after HS diagnosis. Patients with
the mild form of the disease were asymptomatic,
showing a mild compensated hemolysis. Typical
HS patients presented a mild to moderate anemia
because of uncompensated hemolysis. The severe
form of HS presented a transfusion-dependent
anemia. The hematological and biochemical criteria
used for classiﬁcation are referred in Gallagher and
Forget (1).
Among the 81 subjects, we found 20 adults (nine
had been splenectomized) and 31 children (six had
been splenectomized) to be HS patients. Three HS
patients, classiﬁed as mild, had been splenectom-
ized in adulthood, as they developed a symptomatic
vesicular litiasis. Three severe HS patients had not
undergone splenectomy, as their age was not
compatible with that procedure.
The hematological and biochemical values of
patients at the time of blood collection are presen-
ted. In the case of severe HS patients, there was no
contamination with transfused blood, as the last
transfusion took place at least 4 months before the
collection of blood for our studies.
Fifteen of the studied individuals (13 adults and
two children) were used as controls for basic hema-
tological studies and for bilirubin levels, since they
presented normal clinical and laboratorial ﬁndings
and belonged to the families with a dominant pattern
of inheritance for HS. The controls used for the
electrophoretic analysis of RBC membrane proteins
were from healthy blood bank donors.
Assays
Blood samples [ethylenediaminetetraacetic acid
(EDTA) and heparin as anticoagulants] were col-
lected and processed for the hematological and
biochemical analysis, and to prepare the erythro-
cyte membranes. We evaluated the RBC count,
hemoglobin concentration, the red cell distribution
width (RDW) and the hematimetric indices by
using an automatic blood cell counter (Sysmex
K1000; Sysmex, Hamburg, Germany). The search
for spherocytic cells was performed in Wright
stained blood ﬁlms (15). Reticulocyte count was
performed by microscopic counting on blood
smears after vital staining with new methylene blue
(reticulocyte stain; Sigma, St Louis, MO, USA).
Osmotic fragility test was carried out on fresh
blood and after 24 h of incubation at 37C (16).
Serum concentration of total bilirubin was meas-
ured by routine biochemical procedures. To exclude
immune hemolysis, a direct antiglobulin test was
performed for all cases studied (17).
To prepare the RBC membranes, plasma and
leukocytes were previously isolated from RBCs and
discarded after centrifugation on a double density
gradient (Histopaque 1.077 and 1.119; Sigma).
RBCs were washed in saline solution. The erythro-
cytes were lysed by hypotonic lyses according to
Dodge et al. (18). The membranes obtained were
washed in Dodge buﬀer, adding phenylmethylsul-
phonyl ﬂuoride as a protease inhibitor in the ﬁrst
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two washes, with a ﬁnal concentration of 0.1 mm.
The protein concentration of the RBC membrane
suspensions was determined by the Bradford’s
method (19).
The electrophoretic analysis of the red cell mem-
brane proteins was carried out on a discontinuous
system of polyacrylamide in the presence of sodium
dodecylsulfate (SDS-PAGE), using a 5–15% linear
acrylamide gradient gel and a 3.5–17% exponential
acrylamide gradient gel, according to the Laemmli
and Fairbanks methods, respectively (20, 21). The
proteins were stained with Coomassie brilliant blue,
and scanned (Darkroom CN UV/wl, BioCaptMW
version 99; Vilber Lourmat, Marne-La-Valle´e,
France). The relative amount of each major protein
(as a percentage of total), was quantiﬁed by densi-
tometry (Bio1D++ version 99; Vilber Lourmat,
France).
The electrophoretic analysis for each RBC mem-
brane sample was performed in duplicate gels, and,
in each gel, duplicates of each sample were loaded
alongside with six reference samples (from healthy
blood bank donors). The mean values presented by
the studied subjects were compared with those
presented by the reference samples. Protein deﬁci-
ency was considered signiﬁcant whenever the mean
value of that protein was lower than the mean value
minus 2 · standard deviation (SD) presented by the
reference samples for the same protein (subject
mean protein % value < control mean protein %
value ) 2 · SD). Moreover, the ratios between
membrane protein values, for patients and controls,
were evaluated.
Statistical analysis
Measurements are presented as mean ± SD or as
median values (inter-quartile range). For statistical
analysis, we used the Statistical Package for Social
Sciences, version 12.0. To evaluate the diﬀerences
between groups, we used the Student’s t-test
whenever the parameters presented a Gaussian
distribution and the Mann–Whitney test in the case
of a non-Gaussian distribution, as for bilirubin
values. Spearman’s rank correlation coeﬃcient was
used to evaluate relationships between sets of data.
A P-value of <0.05 was considered as statistically
signiﬁcant.
Results
Patients were diagnosed and classiﬁed as presenting
mild, typical or severe HS, according to hemato-
logical and biochemical data and to their clinical
history (1). We diagnosed 51 subjects as HS
patients, of the 81 studied subjects. The other 30
individuals showed normal clinical and laboratory
ﬁndings (hematological, biochemical and electro-
phoretical analysis of membrane proteins).
In Table 1, we present the biochemical and
hematological values for controls and HS patients,
according to the severity of the disease. For each
group we present the results for splenectomized and
unsplenectomized patients. Worsening of HS was
associated with a reduction in RBC count, hemo-
globin concentration, and a rise in RDW, reticulo-
cyte count, osmotic fragility and total bilirubin
concentration. When compared with controls, all
HS patients showed a signiﬁcantly higher mean cell
hemoglobin concentration (MCHC), RDW, reticu-
locyte count and osmotic fragility.
Twenty-ﬁve HS patients (49%) were classiﬁed as
presenting mild HS, 20 (39%) as typical, and six
(12%) as severe (Table 2). The mild form of HS
was observed in primary band 3 deﬁciency and in
primary ankyrin deﬁciency. The typical form of HS
was observed in primary band 3, ankyrin, spectrin
or in protein 4.2 deﬁciencies. The severe form of HS
was observed in primary deﬁciencies in band 3,
ankyrin or spectrin.
Table 1. Hematological and biochemical data for controls and HS patients according to severity of HS
Group
Erythrocytes
(1012/L)
Hemoglobin
(g/dL)
MCHC
(g/dL)
RDW
(%)
Reticulocytes
(109/L)
Bilirubin
(lmol/L)
Osmotic fragility
Before incubation After 24 h incubation
Controls (n ¼ 15) 4.6 € 0.3 14.1 € 0.9 33.7 € 1.2 12.9 € 0.8 76.2 € 28.6 10.8 (7.8–16.0) 0.416 € 0.019 0.464 € 0.049
Mild HS (n ¼ 25)
22 no spl 4.3 € 0.7 13.0 € 2.0* 35.8 € 1.4*** 15.0 € 2.8** 205.4 € 146.7** 25.8 (7.6–36.5) 0.455 € 0.027** 0.579 € 0.079**
3 spl 4.9 € 0.5 15.3 € 2.1 34.8 € 2.6 12.5 € 1.0 96.5 € 10.3 19.0 (14.6–23.3) 0.495 € 0.004*** 0.648 € 0.074**
Typical HS (n ¼ 20)
11 no spl 3.7 € 0.4*** 10.5 € 1.5*** 36.4 € 1.4*** 19.6 € 2.9*** 378.0 € 147.5*** 34.7 (14.3–71.8)** 0.489 € 0.082* 0.647 € 0.068***
9 spl 5.0 € 0.5* 15.3 € 1.2* 36.1 € 0.9*** 12.3 € 1.0 133.7 € 26.6*** 11.9 (11.0–17.0) 0.554 € 0.090** 0.659 € 0.069***
Severe HS (n ¼ 6)
3 no spl 3.4 € 0.4 10.1 € 4.4 35.8 € 1.5* 20.6 € 4.2 423.1 € 117.7* 51.2 (42.7–118.1)** 0.429 (2 nd) 0.647 € 0.046**
3 spl 4.8 € 0.1 14.8 € 2.1 36.5 € 0.1** 14.2 € 2.3* 96.6 € 43.0 13.1 (10.3–16.0) 0.498 € 0.053* 0.655 € 0.064**
*P < 0.05; **P < 0.01; ***P < 0.001 (HS vs. control).
nd, not done; spl, splenectomized.
Data are presented as mean € SD or median (IQR) values.
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We observed a dominant inheritance pattern for
HS in 14 (67%) of the 21 studied families. In the
other seven families, only molecular studies could
establish whether a recessive or non-dominant
pattern was present, such as a de novo mutation,
as only the propositus presented the disease.
In 18 families (of 21) the clinical presentation of
the disease was similar for all members of the
family. Only in three families, a diﬀerent clinical
presentation among family members was observed
– one presenting a primary band 3 deﬁciency (two
patients with mild HS and a third with typical HS),
another family a primary ankyrin deﬁciency (one
patient with mild HS and two with typical HS) and
the other a spectrin deﬁciency (one patient with
typical HS and another with severe HS).
The analysis of the erythrocyte membrane pro-
teins on SDS-PAGE showed that 34 patients
presented a primary band 3 deﬁciency, ﬁve un-
related individuals and 29 belonging to the studied
families (Table 2). The band 3 deﬁciency was
accompanied by a secondary deﬁciency in protein
4.2 in 33 patients. The only case of isolated band 3
deﬁciency was observed in a patient belonging to a
family in which all the other members presented a
combined deﬁciency. Considering that this patient
presented the lowest band 3 deﬁciency among the
family members (data not shown), it is reasonable
that a combined deﬁciency in protein 4.2 is prob-
ably undetectable.
In 10 patients (unsplenectomized) we observed a
combined deﬁciency in spectrin and protein 4.2,
while in two patients (one was splenectomized)
these protein deﬁciencies were also associated with
ankyrin deﬁciency. In these 12 cases, a primary
ankyrin deﬁciency is probably the cause for HS.
Actually, the patients presenting only combined
spectrin and 4.2 deﬁciencies showed reticulocytosis,
which usually masks the ankyrin deﬁciency. The
combined deﬁciencies in spectrin and protein 4.2
were observed in patients belonging to four families
and in two unrelated patients. An individual from
one of these families also presented ankyrin deﬁci-
ency. The same was observed in one unrelated
subject.
An isolated spectrin deﬁciency was observed in
four patients, one unrelated and the others from
two families. Only in one unrelated patient, was an
isolated protein deﬁciency in protein 4.2 observed.
A further and conventional conﬁrmation of the
results concerning the primary protein deﬁciency
was performed by evaluating the ratios between
membrane protein mean values for patients and
controls, namely spectrin/band 3, ankyrin/band 3,
protein 4.2/band 3. In the case of isolated band 3
deﬁciency, all ratios were higher than controls, and
when combined with protein 4.2 deﬁciency, the
protein 4.2/band 3 ratio was similar or lower than
controls. In the case of ankyrin deﬁciency with
combined deﬁciencies in spectrin and protein 4.2,
all three ratios were lower than controls; when
presenting only combined deﬁciencies in spectrin
and protein 4.2, only spectrin/band 3 and protein
4.2/band 3 ratios were lower than controls. For
isolated spectrin and protein 4.2 deﬁciency, we
found lower ratios of spectrin/band 3 and protein
4.2/band 3, respectively.
Considering the protein deﬁciency underlying the
disease and the clinical classiﬁcation, we observed
that the group of patients showing band 3 deﬁci-
ency, isolated or combined, presented mild HS in
19 patients, while a typical form was observed in 13
cases and a severe disease in two patients. In the
case of isolated spectrin deﬁciency, half showed
typical HS and the other half a severe form of the
disease. The group presenting ankyrin deﬁciency
and/or combined spectrin and protein 4.2 deﬁcien-
cies, included six patients with mild HS, four with
typical HS and two with a severe form of the
disease. A typical form of the disease was observed
in the patient presenting a protein 4.2 deﬁciency.
The study of the ratios between the values of the
deﬁciencies presented by the combined deﬁcient
proteins (band 3/protein 4.2 and spectrin/protein
4.2 for primary band 3 and ankyrin deﬁciencies,
respectively), showed signiﬁcantly diﬀerent values
according to the severity of the disease (Table 3). In
both band 3 and ankyrin primary deﬁciencies, the
ratios between protein deﬁciencies in mild HS
cases presented a balanced ratio (1.10 and 1.02,
Table 2. Characterization of HS patients according
to the severity of the disease and the observed protein
deficiencies
Isolated band 3 or
combined with
protein 4.2 deficiency
Ankyrin and/
or combined spectrin and
protein 4.2 deficiencies
Spectrin
deficiency
Protein 4.2
deficiency Total
Subjects 34 12 4 1 51
Mild HS 19 6 – – 25
Typical HS 13 4 2 1 20
Severe HS 2 2 2 – 6
Unrelated subjects 5 3 1 1 10
Related subjects 29 9 3 – 41
Families 15 (10 AD + 5 ND) 4 (3 AD + 1 ND) 2 (1AD + 1 ND) – 21
AD, autosomal dominant pattern of inheritance; ND, recessive or non-dominant pattern of inheritance.
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respectively), reﬂecting equivalent values in protein
deﬁciencies. In typical HS we observed signiﬁcantly
unbalanced ratios (0.74 and 0.50, respectively),
when compared with those presented by mild HS.
In severe HS cases, a trend towards even more
unbalanced ratios was observed (0.49 and 0.48,
respectively). In addition, we found that the ratios
between protein deﬁciencies were signiﬁcantly
inversely correlated with the severity of the disease
(r ¼ )0.590, P < 0.001 in primary band 3 deﬁ-
ciency; r ¼ )0.824, P < 0.001 in primary ankyrin
deﬁciency).
As referred, in three families we observed a
diﬀerent clinical expression of HS among family
members. It was interesting to ﬁnd that in ﬁve of
the six patients, the ratio between the value of
protein deﬁciencies decreases according to the
clinical presentation.
Discussion
Hereditary spherocytosis, an inherited hemolytic
anemia, usually presents an autosomal dominant
inheritance pattern. This pattern of inheritance was
observed in 67% (14/21 families) of our studied
families. Similar values were reported in Europeans
(75%) (1, 3–5), Brazilians (64%) (22) and Mexicans
(59%) (23). A lower value was reported for
Koreans (31%) (24).
Seven of the studied families may present a
recessive or non-dominant inheritance pattern, as
only the propositus presented the disease. In these
cases, only the molecular studies could clarify the
inheritance pattern. Concerning the 10 unrelated
HS patients studied, only a family study, eventually
followed by molecular studies, could clarify their
inheritance pattern.
Clinically, HS may present a broad spectrum,
being usually classiﬁed as mild, typical or severe,
according to clinical and analytical follow-up.
About half of our HS patients presented the mild
form of the disease (Table 2), while a slightly lower
number of patients presented the typical form
(39%). The severe form was observed in the lowest
number of patients (12%). All the usual protein
deﬁciencies underlying HS were observed in the
mild, typical and severe forms of the disease,
excepting for spectrin and for protein 4.2 deﬁcien-
cies. Our results are in accordance with literature
(25), showing that the same protein deﬁciency may
account for a mild, typical or severe presentation of
the disease. However, the prevalence of mild,
typical and severe HS in our studied population
stray from reported values, which present typical
HS as the most common presentation (50–60%),
followed by the mild (20–30%) and the severe form
(5–7%) (8).
The hematological features used to diagnose HS
include the observation of spherocytes in blood
smears and an increased erythrocyte osmotic fra-
gility. Some other parameters usually included in
the hematologic study, are also of considerable
value in the diagnosis and in the clinical classiﬁca-
tion of HS (25, 26). We found in unsplenectomized
HS patients a signiﬁcant increase in reticulocyte
count and RDW when compared with controls,
and the value of those rises seem to be in accord-
ance with the severity of the disease (Table 1).
It is accepted nowadays, that the most commonly
aﬀected proteins in HS are ankyrin and band 3
protein, and less frequently spectrin and protein 4.2
(1, 4, 12, 27–30). In our HS studied patients, we
also found band 3 protein and ankyrin deﬁciencies
as the major causes for HS, followed by spectrin
and protein 4.2 deﬁciencies (Table 2). However, in
our sample population, band 3 deﬁciency presented
a higher frequency than ankyrin deﬁciency. This
may reﬂect the distribution of the ethnic groups
living in the north of Portugal, although it may
change as the patient group size increases.
Although the clinical severity of HS diﬀers
among families, it is quite similar within a family
presenting an autosomal dominant pattern of
inheritance (5, 8). We observed a similar clinical
expression in 18 of 21 families. A diﬀerent clinical
expression was observed in individuals belonging to
three families, one of them presenting a primary
deﬁciency in band 3, another family in ankyrin and
the other in spectrin.
The diﬀerences in HS clinical expression may
have resulted from an heterozygous combination of
interacting alleles, a common allele and a weak
allele (31, 32). Clinical diﬀerences may also result
from a coinheritance of another erythrocyte dis-
order, able to aﬀect the HS phenotype. Molecular
studies have showed that diﬀerent clinical expres-
sion within a given family, for a given mutation, in
apparently recessive HS could result from de novo
mutations (5, 6, 29). To clarify the diﬀerent clinical
expression observed in the individuals of our three
families, it would be necessary to perform mole-
cular studies, as we did not ﬁnd an association with
Table 3. Ratios between the protein deficiencies in mild, typical and severe HS
caused by primary band 3 and ankyrin deficiencies
Mild HS (n ¼ 19) Typical HS (n ¼ 13) Severe HS (n ¼ 2)
Band 3/protein 4.2 in band 3 primary deficiency
1.10 € 0.37 0.74 € 0.22** 0.49 € 0.08
Mild HS (n ¼ 6) Typical HS (n ¼ 4) Severe HS (n ¼ 2)
Spectrin/protein 4.2 in ankyrin primary deficiency
1.02 € 0.22 0.50 € 0.09** 0.48 € 0.37
**P < 0.01 (mild HS vs. typical HS).
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another erythroid pathology in any individual.
Considering the variability of HS clinical expres-
sion between families and within the same family, it
would be important to foresee the protein deﬁci-
ency underlying HS, on the basis of preliminary
easy, low-priced and less-time-consuming tests,
such as the erythrocyte membrane protein studies
instead of on the basis of expensive molecular
studies. In linear and exponential gradient gels, we
were able to identify and quantify the most likely
primary protein deﬁciency and/or the secondary
protein deﬁciencies by SDS-PAGE (10, 11). This
knowledge would allow the focusing of the molecu-
lar studies on the probable gene underlying HS.
When HS is caused by mutations in the ANK1
gene, the a- and b-chains of spectrin and protein 4.2
are decreased in a secondary way. In the case of HS
associated with mutations in SLC4A1 gene, the
primary deﬁciency in band 3 is often associated to a
secondary deﬁciency in protein 4.2. A rough
equivalence between the value of the primary and/
or secondary protein deﬁciencies has been reported
(32). In the present study, we observed that a
balance between the value of protein deﬁciencies in
mild HS because of primary band 3 and ankyrin
deﬁciencies, while in typical and severe HS a trend
to an unbalance was found, suggesting the import-
ance of a balanced interaction between proteins in
the clinical outcome of the disease (Table 3).
Moreover, we found a signiﬁcant negative correla-
tion between the balance of protein deﬁciencies and
the severity of the disease.
A gene mutation may impose an insuﬃcient
synthesis in mRNA or an abnormal protein synthe-
sis. In the ﬁrst case, the reduced protein synthesis
will lead to a membrane deﬁcient in that protein,
and probably in interacting proteins, which would
have not enough binding sites. Equivalent protein
deﬁciencies in interacting membrane proteins would
be observed, and the cell would present a normal
interaction between the deﬁcient proteins. However,
when an abnormal membrane protein molecule is
synthesized, it probably prevents a normal linkage
with other interacting membrane proteins, as it may
no longer have the binding site for the interacting
proteins. This would lead to a reduced incorpor-
ation of those proteins into the membrane, and,
therefore, to a higher deﬁency, reﬂected by an
unbalance between the primary and the secondary
protein deﬁciencies. Thus, when the mutated protein
fails to normally interact with other proteins, the
membrane instability would probably be enhanced
leading to a severe form of the disease. It is
reasonable that an erythrocyte with normal mem-
brane protein interactions between the deﬁcient
proteins would be more resistant than erythrocytes
presenting altered membrane protein interactions.
In conclusion, our data suggest that the loss of a
balanced protein interaction between the deﬁcient
proteins is accompanied by worsening of the
disease. Further studies are warranted to strengthen
the value of the balance between erythrocyte
membrane protein deﬁciencies as an additional
predictor of the clinical outcome in HS.
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